Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jacob J. Adashek"'
Autor:
Pedro Nazareth Aguiar, Mariane Teodoro Fernandes, Jacob J. Adashek, Ana Claudia Barbin Spinosa, Gilberto Lopes, Auro Del Giglio, Barbara de Souza Gutierres, Carmelia Maria Noia Barreto
Publikováno v:
Drugs in Context, Vol 7, Pp 1-6 (2018)
Drugs in Context
Drugs in Context
In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1916f144f7cc102a8de65e755a7d4a1
https://www.drugsincontext.com/a-paradigm-shift-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-hr-her2-advanced-breast-cancer-a-review-of-cdk-inhibitors
https://www.drugsincontext.com/a-paradigm-shift-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-hr-her2-advanced-breast-cancer-a-review-of-cdk-inhibitors
Autor:
Noor Khalid, Razelle Kurzrock, Jacob J. Adashek, Suzanna Lee, Shumei Kato, Jason K. Sicklick, Van Thomas Nguyen, Ryosuke Okamura
Publikováno v:
JCI insight, vol 6, iss 1
JCI Insight, Vol 6, Iss 1 (2021)
JCI Insight
JCI Insight, Vol 6, Iss 1 (2021)
JCI Insight
BACKGROUND Although CDK4/6 inhibitors are an established treatment for hormone receptor–positive, HER2-negative metastatic breast cancers, their benefit in other malignancies remains limited.METHODS We investigated factors associated with clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66de530f4ac6efbc82971e89d868547b
https://escholarship.org/uc/item/66p2z8d2
https://escholarship.org/uc/item/66p2z8d2
Publikováno v:
Genome Medicine
Genome medicine, vol 12, iss 1
Genome Medicine, Vol 12, Iss 1, Pp 1-19 (2020)
Genome medicine, vol 12, iss 1
Genome Medicine, Vol 12, Iss 1, Pp 1-19 (2020)
Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures. Intriguingly, rapidly emerging data indicate that altered genes represent
Autor:
Gilberto Lopes, Jacob J. Adashek, Ramon Andrade de Mello, Pedro Castelo-Branco, Pedro Nazareth Aguiar
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Submitted by Emilia Lucia Mariano Pacheco (epacheco@ualg.pt) on 2019-11-13T15:25:53Z No. of bitstreams: 1 fon-2019-0044.pdf: 1292236 bytes, checksum: ea9fdf88c4e6a4b43d5639c9d6160d5f (MD5) Approved for entry into archive by Filipa Custódio (fccustod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5b1076fe7d04405adfc963cff2dfde7
Autor:
Saihitha Veerapaneni, Neeraj Agarwal, Roberto Nussenzveig, Christopher Szeto, Sumanta K. Pal, Elias Obeid, Sandeep K. Reddy, Jacob J. Adashek
Publikováno v:
Molecular Cancer Therapeutics. 18:B093-B093
Background: BC and CRC are heterogeneous diseases with several distinct disease subtypes. A 50-gene qPCR assay (PAM50) identifies 5 intrinsic biological subtypes: luminal A, luminal B, HER2-enriched, basal-like, and normal-like in breast cancer. Cons
Autor:
Mariane Teodoro Fernandes, Jacob J Adashek, Carmelia Maria Noia Barreto, Ana Cláudia Barbin Spinosa, Barbara de Souza Gutierres, Gilberto Lopes, Auro del Giglio, Pedro Nazareth Aguiar Jr
Publikováno v:
Drugs in Context, Vol 7, Pp 1-6 (2018)
In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are or
Externí odkaz:
https://doaj.org/article/5e1b8b58681343a2a90c0ae761a28613